Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO6IM1)

Drug Name

group E 1682-2106 Drug Info

Synonyms

CHEMBL1770295; 3-methyl-2-[(5Z)-5-(1-methyl-2-oxoindol-3-ylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid; AC1NT1C6; GTPL5827; MolPort-000-500-334; BDBM50418364; AKOS016308025; AKOS002200571; ST50147548; UNM000000513101; group E 1682-2106 [PMID:16118363]; 3-METHYL-2-[(5Z)-5-(1-METHYL-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)-4-OXO-2-THIOXO-1,3-THIAZOLIDIN-3-YL]BUTANOIC ACID; 3-methyl-2-[5-(1-methyl-2-oxobenzo[d]azolin-3-ylidene)-4-oxo-2-thioxo(1,3-thia zolidin-3-yl)]butanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5322194
TTD Drug ID: DMO6IM1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting N-formyl peptide receptor (FPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rebamipide	DM2GHCR	Peptic ulcer	DA61	Phase 3	[2]
PMID22607879CR-(-)-5f	DM7OJ5Q	Discovery agent	N.A.	Investigative	[3]
fMet-Leu-Phe	DMQ391A	N. A.	N. A.	Investigative	[4]
pyrazolone, 1	DMLFQKU	Discovery agent	N.A.	Investigative	[5]
BVT173187	DMULZOP	Discovery agent	N.A.	Investigative	[6]
CGEN-855	DM4FMPJ	Inflammation	1A00-CA43.1	Investigative	[7]
AG-11/03	DMZINUY	Discovery agent	N.A.	Investigative	[8]
methionine benzimidazole 6	DMEIP6H	Discovery agent	N.A.	Investigative	[9]
AG-09/1	DMW7H28	Discovery agent	N.A.	Investigative	[10]
diamide 7	DM4EX8Y	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-formyl peptide receptor (FPR1)	TT5Y4EM	FPR1_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol. 2005 Nov;68(5):1301-10.
2	Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94.
3	Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92.
4	Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry. 1980 May 27;19(11):2404-10.
5	Functional characterization of three mouse formyl peptide receptors. Mol Pharmacol. 2013 Feb;83(2):389-98.
6	A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. Biochem Pharmacol. 2012 Jun 15;83(12):1655-62.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 222).
8	Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1. J Mol Model. 2012 Jun;18(6):2831-43.
9	Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett. 2011 May 15;21(10):2991-7.
10	Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol. 2010 Feb;77(2):159-70.